Recent Research Analysts’ Ratings Changes for Illumina (ILMN)

Several analysts have recently updated their ratings and price targets for Illumina (NASDAQ: ILMN):

  • 1/30/2019 – Illumina was upgraded by analysts at Leerink Swann to an “outperform” rating. They now have a $365.00 price target on the stock, down previously from $380.00.
  • 1/30/2019 – Illumina was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Illumina exited the fourth quarter of 2018 on a mixed note with earnings lagging the Zacks Consensus Estimate and revenues ahead of the mark. Top line growth was visible across the company’s high throughput, mid throughput and low throughput categories. The company observed strong demand for sequencing and array systems, consumables and services. Meanwhile HiSeq to NovaSeq upgrade cycle is progressing well and NextSeq placements are strong. We are also looking forward to the company's newly-inked Pacific Biosciences deal. In the past year, Illumina has outperformed its industry. On the flip side, HiSeq consumables are continuing with their expected decline. Seasonality in DTC functionality continues to dent Illumina’s microarray sales. Funding issues restrict growth. The company is operating in a tough competitive landscape.”
  • 1/30/2019 – Illumina had its “buy” rating reaffirmed by analysts at Bank of America Corp. They now have a $355.00 price target on the stock.
  • 1/29/2019 – Illumina was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/25/2019 – Illumina was downgraded by analysts at Deutsche Bank AG from a “buy” rating to a “hold” rating. They now have a $296.53 price target on the stock.
  • 1/11/2019 – Illumina was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $347.00 price target on the stock. According to Zacks, “In the past six months, Illumina has outperformed its industry. The company has received regulatory approval for its next-generation sequencing (NGS) system — MiSeqDx in China. Illumina also released the S4 200 cycle kit for the NovaSeq platform in the quarter. Additionally, improving margins buoy optimism. Further, the company’s raised 2018 EPS guidance indicates that the company will deliver solid results in the quarters to come. On the flip side, seasonality in DTC functionality continues to dent Illumina’s microarray sales. Funding issues restrict growth. The company, which is currently a bit overvalued, is operating in a tough competitive landscape.”
  • 1/7/2019 – Illumina had its price target lowered by analysts at Morgan Stanley from $320.00 to $288.00. They now have an “equal weight” rating on the stock.
  • 1/3/2019 – Illumina was upgraded by analysts at UBS Group AG from a “neutral” rating to a “buy” rating. They now have a $370.00 price target on the stock, up previously from $340.00.
  • 12/31/2018 – Illumina was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “In the past six months, Illumina has outperformed its industry. The company has received regulatory approval for its next-generation sequencing (NGS) system — MiSeqDx in China. Illumina also released the S4 200 cycle kit for the NovaSeq platform in the quarter. Additionally, improving margins buoy optimism. Further, the company’s raised 2018 EPS guidance indicates that the company will deliver solid results in the quarters to come. On the flip side, seasonality in DTC functionality continues to dent Illumina’s microarray sales. Funding issues restrict growth. The company, which is currently a bit overvalued, is operating in a tough competitive landscape.”

ILMN opened at $284.10 on Monday. The company has a market capitalization of $41.76 billion, a price-to-earnings ratio of 49.67, a price-to-earnings-growth ratio of 2.03 and a beta of 1.20. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 0.23. Illumina, Inc. has a 12-month low of $210.08 and a 12-month high of $372.61.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.04). Illumina had a net margin of 24.79% and a return on equity of 24.51%. The business had revenue of $867.00 million during the quarter, compared to analyst estimates of $865.33 million. During the same period last year, the business earned $1.44 EPS. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. Research analysts expect that Illumina, Inc. will post 6.51 EPS for the current fiscal year.

In other Illumina news, EVP Omead Ostadan sold 644 shares of Illumina stock in a transaction on Friday, November 23rd. The stock was sold at an average price of $306.74, for a total value of $197,540.56. Following the completion of the transaction, the executive vice president now owns 22,257 shares in the company, valued at approximately $6,827,112.18. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Charles Dadswell sold 124 shares of Illumina stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $294.71, for a total value of $36,544.04. Following the completion of the transaction, the senior vice president now owns 7,003 shares of the company’s stock, valued at approximately $2,063,854.13. The disclosure for this sale can be found here. Insiders have sold a total of 39,247 shares of company stock worth $12,057,866 in the last three months. 0.54% of the stock is owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Advisors Asset Management Inc. raised its stake in Illumina by 23.8% in the second quarter. Advisors Asset Management Inc. now owns 41,850 shares of the life sciences company’s stock valued at $11,688,000 after buying an additional 8,042 shares during the period. Gofen & Glossberg LLC IL acquired a new position in shares of Illumina in the third quarter valued at approximately $260,000. Winslow Evans & Crocker Inc. acquired a new position in shares of Illumina in the third quarter valued at approximately $368,000. Cookson Peirce & Co. Inc. grew its position in shares of Illumina by 18.7% in the third quarter. Cookson Peirce & Co. Inc. now owns 81,230 shares of the life sciences company’s stock valued at $29,816,000 after purchasing an additional 12,780 shares during the last quarter. Finally, Puzo Michael J grew its position in shares of Illumina by 1.8% in the third quarter. Puzo Michael J now owns 10,303 shares of the life sciences company’s stock valued at $3,782,000 after purchasing an additional 180 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Read More: Terms to Better Understand Call Options

Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply